prognostic signature
AccuStem, University Hospitals Partner to Establish Clinical Utility of Cancer Recurrence Test
University Hospitals will provide cancer tissue samples with paired clinical outcomes for further clinical validation of StemPrintER, initially focusing on breast cancer.
Prominent players in the market cited maturing validity data and updated guidelines that have led to growing awareness among doctors and patients.
The company hopes that it can persuade urology practices to go with its suite of assays by covering a fuller range of treatment decision points.
Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test
The test will be covered by the VA for five years to determine the risk of recurrence in early-stage lung cancer patients after surgery.
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Sep 9, 2019
Sep 5, 2019
OncoCyte to Acquire Razor Genomics
Dec 11, 2018
PredictImmune Gains CE-IVD Mark for IBD Test
Oct 24, 2018
Apr 25, 2017